NDAINTRAVENOUSSOLUTION
Approved
Aug 2019
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
GALLIUM GA 68 EDOTREOTIDE (edotreotide gallium ga-68) by Imagin Medical is 68 dotatoc binds to somatostatin receptors, with highest affinity (k i = 2. First approved in 2019.
Drug data last refreshed 8m ago · AI intelligence enriched 8m ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Gallium GA-68 Edotreotide is a positron emission tomography (PET) radiopharmaceutical that binds to somatostatin receptor subtype 2 (sstr2) with high affinity (Ki = 2.5±0.5 nM) on neuroendocrine tumor cells. It enables molecular imaging of somatostatin receptor-expressing malignancies through 68Ga-mediated PET detection. The drug allows clinicians to identify and localize neuroendocrine tumors that overexpress somatostatin receptors.
PeakPost-LOE
Product is at peak commercial maturity with moderate competitive pressure (30/100), suggesting stable but not explosive team growth opportunities.
Mechanism of Action
68 DOTATOC binds to somatostatin receptors, with highest affinity (K i = 2.5± 0.5 nanomolar) for subtype 2 receptors (sstr2). Ga 68 DOTATOC binds to cells that express somatostatin receptors including malignant neuroendocrine cells, which overexpress sstr2 receptors. Gallium 68 is a β+ emitting…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Gallium GA-68 Edotreotide positions you in the specialized radiopharmaceutical and oncology diagnostic space, with exposure to niche healthcare infrastructure (PET centers, nuclear medicine). The peak-stage product with approaching LOE means near-term stability but long-term role evolution toward post-LOE strategies.
Brand Manager
Worked on GALLIUM GA 68 EDOTREOTIDE at Imagin Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.